|
gptkbp:instanceOf
|
gptkb:drug
prodrug
|
|
gptkbp:abusePotential
|
high
|
|
gptkbp:approvalYear
|
2007
|
|
gptkbp:approvedBy
|
gptkb:FDA
|
|
gptkbp:ATCCode
|
N06BA12
|
|
gptkbp:availableOn
|
capsule
chewable tablet
|
|
gptkbp:bioavailability
|
high (as dextroamphetamine)
|
|
gptkbp:brand
|
gptkb:Vyvanse
|
|
gptkbp:CASNumber
|
608137-32-3
|
|
gptkbp:chemicalFormula
|
C15H25N3O
|
|
gptkbp:contraindication
|
gptkb:cardiovascular_disease
hypertension
glaucoma
hyperthyroidism
|
|
gptkbp:developedBy
|
gptkb:New_River_Pharmaceuticals
|
|
gptkbp:discoveredBy
|
gptkb:New_River_Pharmaceuticals
|
|
gptkbp:drugClass
|
amphetamine
stimulant
|
|
gptkbp:eliminationHalfLife
|
less than 1 hour (lisdexamfetamine), 8-13 hours (dextroamphetamine)
|
|
gptkbp:excretion
|
urine
|
|
https://www.w3.org/2000/01/rdf-schema#label
|
lisdexamfetamine
|
|
gptkbp:KEGGID
|
D06674
|
|
gptkbp:legalStatus
|
Schedule II controlled substance (US)
|
|
gptkbp:marketedAs
|
gptkb:Takeda_Pharmaceutical_Company
2007
|
|
gptkbp:mechanismOfAction
|
stimulant
increases dopamine and norepinephrine
|
|
gptkbp:metabolism
|
gptkb:dextroamphetamine
|
|
gptkbp:patentExpired
|
2023 (US)
|
|
gptkbp:pregnancyCategory
|
C (US)
B3 (Australia)
|
|
gptkbp:proteinBinding
|
low
|
|
gptkbp:PubChem_CID
|
gptkb:CHEMBL1201209
11597682
9769047
DB01255
|
|
gptkbp:routeOfAdministration
|
oral
|
|
gptkbp:sideEffect
|
anxiety
weight loss
insomnia
dry mouth
irritability
decreased appetite
|
|
gptkbp:UNII
|
H8Y6U1YUXL
|
|
gptkbp:usedFor
|
gptkb:attention_deficit_hyperactivity_disorder
binge eating disorder
|
|
gptkbp:bfsParent
|
gptkb:Dexmethylphenidate
gptkb:Vyvanse
|
|
gptkbp:bfsLayer
|
7
|